News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
15,355 Results
Type
Article (2756)
Company Profile (3)
Press Release (12596)
Multimedia
Podcasts (17)
Webinars (1)
Section
Business (5450)
Career Advice (73)
Deals (939)
Drug Delivery (10)
Drug Development (2487)
Employer Resources (6)
FDA (455)
Job Trends (713)
News (9184)
Policy (1063)
Tag
Academia (42)
Accelerated approval (1)
Adcomms (1)
Allergies (8)
Alliances (1400)
ALS (7)
Alzheimer's disease (27)
Antibody-drug conjugate (ADC) (10)
Approvals (467)
Artificial intelligence (27)
Autoimmune disease (22)
Bankruptcy (6)
Best Places to Work (492)
Biosimilars (6)
Biotechnology (1)
Brain cancer (2)
Breast cancer (4)
Cancer (107)
Cardiovascular disease (14)
Career advice (54)
CAR-T (5)
CDC (5)
Cell therapy (14)
Clinical research (2070)
Collaboration (57)
Compensation (7)
Complete response letters (8)
COVID-19 (214)
CRISPR (6)
C-suite (47)
Cystic fibrosis (2)
Data (155)
Denatured (1)
Depression (2)
Diabetes (29)
Diagnostics (61)
Digital health (1)
Diversity, equity & inclusion (1)
Drug discovery (10)
Drug pricing (22)
Earnings (1443)
Editorial (7)
Employer branding (2)
Employer resources (5)
Events (1172)
Executive appointments (49)
FDA (562)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (1)
Frontotemporal dementia (4)
Funding (63)
Gene editing (10)
Generative AI (3)
Gene therapy (20)
GLP-1 (91)
Government (263)
Grass and pollen (1)
Guidances (16)
Healthcare (293)
Huntington's disease (1)
Immunology and inflammation (52)
Immuno-oncology (4)
Indications (9)
Infectious disease (244)
Inflammatory bowel disease (11)
Inflation Reduction Act (1)
Influenza (12)
Intellectual property (2)
Interviews (12)
IPO (230)
IRA (4)
Job creations (244)
Job search strategy (54)
JPM (5)
Labor market (1)
Layoffs (43)
Legal (253)
Liver cancer (2)
Longevity (1)
Lung cancer (16)
Lymphoma (13)
Machine learning (4)
Management (2)
Manufacturing (36)
MASH (3)
Medical device (61)
Medtech (62)
Mergers & acquisitions (735)
Metabolic disorders (64)
Multiple sclerosis (23)
Neurodegenerative disease (20)
Neuropsychiatric disorders (6)
Neuroscience (80)
Neurotech (1)
NextGen: Class of 2026 (158)
Non-profit (66)
Obesity (27)
Opinion (29)
Ovarian cancer (4)
Pain (2)
Pancreatic cancer (5)
Parkinson's disease (2)
Patents (6)
Patient recruitment (5)
Peanut (1)
People (2364)
Pharmaceutical (1)
Pharmacy benefit managers (2)
Phase 1 (554)
Phase 2 (787)
Phase 3 (981)
Pipeline (172)
Policy (25)
Postmarket research (167)
Preclinical (176)
Prostate cancer (1)
Psychedelics (1)
Radiopharmaceuticals (12)
Rare diseases (45)
Real estate (165)
Recruiting (3)
Regulatory (800)
Reports (2)
Research institute (44)
Resumes & cover letters (12)
RNA editing (1)
RSV (12)
Series A (15)
Series B (14)
Sickle cell disease (3)
Special edition (4)
Spinal muscular atrophy (2)
Startups (147)
Supply chain (4)
Tariffs (10)
The Weekly (16)
Vaccines (127)
Venture capital (12)
Weight loss (19)
Date
Last 7 days (15)
Last 30 days (67)
Last 365 days (841)
2026 (90)
2025 (846)
2024 (793)
2023 (767)
2022 (1576)
2021 (1390)
2020 (1181)
2019 (830)
2018 (687)
2017 (866)
2016 (801)
2015 (947)
2014 (599)
2013 (555)
2012 (573)
2011 (603)
2010 (522)
Location
Africa (57)
Asia (869)
Australia (104)
California (330)
Canada (26)
China (79)
Colorado (2)
Connecticut (2)
Delaware (2)
Europe (4474)
Florida (13)
Illinois (5)
India (1)
Indiana (5)
Japan (9)
Kansas (3)
Maryland (26)
Massachusetts (124)
Michigan (1)
Minnesota (3)
Nebraska (1)
New Hampshire (1)
New Jersey (35)
New York (135)
North Carolina (6)
Northern California (251)
Ohio (1)
Pennsylvania (25)
South America (62)
Southern California (67)
Texas (9)
United States (725)
Utah (8)
Virginia (5)
Washington D.C. (1)
Washington State (5)
Wisconsin (2)
15,355 Results for "sanofi us.rss".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Vaccines
Sanofi Suffers Another Sales Dip for ‘Gift to Public Health’ Vaccines
Sanofi’s vaccine sales dipped 2.5% in 2025, with almost all immunization products declining. Nevertheless, CEO Paul Hudson doubled down on his support for vaccine development.
January 29, 2026
·
2 min read
·
Tristan Manalac
Vaccines
JPM26: Sanofi’s CEO Keen To Buy the Dip as Vaccine Rhetoric Impacts Short-Term Sales
Buying vaccine biotech Dynavax was an easy choice for Sanofi despite anti-vaccine moves by the Trump administration.
January 14, 2026
·
3 min read
·
Annalee Armstrong
Rare disease
Sanofi Rare Disease Drug Scores a Hit and a Miss in Phase III Tests
Sanofi will take venglustat to regulators for Gaucher disease but an application for Fabry disease is less clear after the failure of a Phase III trial.
February 2, 2026
·
1 min read
·
Annalee Armstrong
Multiple sclerosis
Sanofi’s MS Drug Fails Phase III Trial, While FDA Again Delays Approval Application
Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the disease and yet another regulatory setback in another.
December 15, 2025
·
2 min read
·
Annalee Armstrong
Vaccines
Sanofi Moves Away From mRNA Flu Vaccine as CEO Projects Confidence
Despite Sanofi CEO Paul Hudson’s confidence in vaccines, the French pharma has cut at least one mRNA flu shot program.
January 30, 2026
·
2 min read
·
Tristan Manalac
Multiple sclerosis
Sanofi’s MS Drug Tripped Up by Toxicities, Unclear Benefit, Rejection Letter Reveals
Last month, the FDA declined to approve Sanofi’s tolebrutinib for a specific form of multiple sclerosis. In a recently published complete response letter, the agency detailed its reasoning behind the rejection.
January 6, 2026
·
3 min read
·
Tristan Manalac
Earnings
Sanofi’s Legacy Vaccine Sales Decline As Americans Skip Flu Shots
Sales of Sanofi’s COVID-19 and flu vaccines fell 17% in the third quarter amid declining vaccination rates and pricing pressures in Europe.
October 24, 2025
·
2 min read
·
Annalee Armstrong
Autoimmune disease
Sanofi Taps Dren Again in up to $1.7B Autoimmune Partnership
Sanofi bought Dren’s DR-0201 program earlier this year for $600 million upfront and is running two Phase I trials in undisclosed inflammatory indications.
December 15, 2025
·
1 min read
·
Annalee Armstrong
Immunology and inflammation
Sanofi’s Anti-OX40 Blocker Falls ‘Well Below Expectations’ in Phase III Eczema Study
Despite hitting its efficacy targets in the Phase III COAST-1 study, Sanofi’s amlitelimab remains “meaningfully inferior” to Dupixent, according to analysts at Leerink Partners.
September 5, 2025
·
2 min read
·
Tristan Manalac
Radiopharmaceuticals
Sanofi Comes for Novartis’ Radiopharma Crown With ‘Clinically Meaningful’ Pancreatic Tumor Data
Sanofi’s Orano Med-partnered radioligand therapy AlphaMedix achieved all primary efficacy endpoints, which included a measure of overall response rate, in the mid-stage ALPHAMEDIX-02 study.
October 8, 2025
·
2 min read
·
Annalee Armstrong
1 of 1,536
Next
